CONFLICT OF INTEREST STATEMENT

RKM is the chair of the RCOG Scientific Advisory Committee, Deputy National Specialty Lead for Reproductive Health and Childbirth Clinical Research Network NIHR and President of the British Maternal Fetal Medicine Society. EJ received a NERC RESPIRE grant. CL is chief investigator of the TRUFFLE 2 study of moderate preterm fetal growth restriction and has received NIHR HTA funding to Imperial College London. VM has declared no conflicts of interest. GS has received the following funding, paid to their institution: contract from Wellcome Leap for maternal serum proteomics to understand and to predict pregnancy complications leading to stillbirth, contract from Roche Diagnostics Ltd. For an Investigator Initiated Study Agreement: Pregnancy Outcome Prediction Study 2; grants from MRC for pre-labour invasion of the human uterus by Streptococcus agalactiae, from the Wellcome Trust for the evaluation and development of novel diagnostic methods to understand and prevent placentally-related complications of human pregnancy, from the NIHR Cambridge Biomedical Research Centre as Theme Leader for Women's Health and Paediatrics and from the MRC for a quantitative serum metabolite ratio to predict fetal growth abnormalities. They have also personally received a consulting fee from GSK as consultant and member of expert panel for RSV vaccination in pregnancy.

中文翻译：

---

小于胎龄胎儿和生长受限胎儿的调查和护理（绿顶指南第31号）

利益冲突声明

RKM 是 RCOG 科学咨询委员会主席、NIHR 生殖健康和分娩临床研究网络国家专业副负责人以及英国母胎医学学会主席。 EJ 获得了 NERC RESPIRE 资助。 CL 是中度早产儿生长受限 TRUFFLE 2 研究的首席研究员，并获得了 NIHR HTA 向伦敦帝国理工学院提供的资助。 VM 已声明不存在利益冲突。 GS 已收到支付给其机构的以下资金：来自 Wellcome Leap 的母体血清蛋白质组学合同，以了解和预测导致死产的妊娠并发症；来自罗氏诊断有限公司的合同。研究者发起的研究协议：妊娠结果预测研究 2；来自 MRC 的资助，用于无乳链球菌在产前侵入人类子宫；来自 Wellcome Trust 的资助，用于评估和开发新的诊断方法，以了解和预防人类妊娠的胎盘相关并发症；来自 NIHR 剑桥生物医学研究中心的资助妇女健康和儿科领域的领导者以及 MRC 的定量血清代谢物比率以预测胎儿生长异常。他们还亲自作为妊娠期 RSV 疫苗接种的顾问和专家组成员从 GSK 获得咨询费。